Clinical outcomes


Select item(s)
Key Findings
No significant improvements were observed in clinical status (in terms of WHO 7-point ordinal scale) between different treatment groups (Lopinavir/Ritonavir, IFN-Ŗ-1a, Hydroxychloroquine) and control group patients on the 15th day and 29th day.
PMID
Title Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Author(s) name-
Journal
Impact factor
Citation count
Date of publishing-
Ivermectin-treated group patients had a lower mortality rate compared to the control group patients. Mortality also was lower in the subgroup of Ivermectin-treated patients with severe pulmonary involvement.
PMID 33065103
Title Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study
Author(s) nameRajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ.
Journal Chest
Impact factor7.22
Citation count19
Date of publishing2021 Jan
No patients in the fluvoxamine-treated group had clinical deterioration, whereas 8.3% of patients in the placebo group showed clinical deterioration.
PMID 33180097
Title Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
Author(s) nameLenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM.
Journal JAMA
Impact factor14.78
Citation count6
Date of publishing2020 Dec 8
Patients treated with Anakinra within 36 hours after the onset of acute hypoxemic respiratory failure showed better improvement (without mechanical ventilation).
PMID 32602262
Title Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID19: A Case Series
Author(s) nameNavarro-Mill√°n I, Sattui SE, Lakhanpal A, Zisa D, Siegel CH, Crow MK.
Journal Arthritis Rheumatol
Impact factor7.34
Citation count11
Date of publishing2020 Dec
Clinical outcomes in patients treated with IFX-1 (vilobelimab) showed a positive (but not significant) difference compared to the control group. The mortality by 28 days was 13% for the IFX-1 group and 27% for the control group. IFX-1 resulted in C5a inhibition and appeared to be safe and promising in treating severe COVID-19 patients.
PMID 33015643
Title Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Author(s) nameVlaar APJ, de Bruin S, Busch M, Timmermans SAMEG, van Zeggeren IE, Koning R, Ter Horst L, Bulle EB, van Baarle FEHP, van de Poll MCG, Kemper EM, van der Horst ICC, Schultz MJ, Horn J, Paulus F, Bos LD, Wiersinga WJ, Witzenrath M, Rueckinger S, Pilz K, Brouwer MC, Guo RF, Heunks L, van Paassen P, Riedemann NC, van de Beek D.
Journal Lancet Rheumatol
Impact factor<3years
Citation count8
Date of publishing2020 Dec
55.6% and 88.9% of patients showed positive outcomes when treated with Anakinra (ANK) and Tocilizumab (TCZ), respectively. Two patients who did not improve by TCZ drug treatment were treated successfully by ANK treatment. ANK is a potential alternative drug for treating patients who are not responding to TCZ.
PMID 32843231
Title High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
Author(s) nameIglesias-Juli√°n E, L√≥pez-Veloso M, de-la-Torre-Ferrera N, Barraza-Vengoechea JC, Delgado-L√≥pez PD, Colazo-Burlato M, Ubeira-Iglesias M, Montero-Balad√≠a M, Lorenzo-Mart√≠n A, Minguito-de-la-Iglesia J, Garc√≠a-Mu√Īoz JP, Sanllorente-Sebasti√°n R, Vicente-Gonz√°lez B, Alem√°n-Alem√°n A, Buz√≥n-Mart√≠n L.
Journal J Autoimmun
Impact factor7.32
Citation count3
Date of publishing2020 Dec
Patients treated with the Remdesivir had better clinical improvement and less mortality than patients in the placebo group.
PMID 32445440
Title Remdesivir for the Treatment of Covid-19 Final Report
Author(s) nameBeigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members.
Journal N Engl J Med
Impact factor37.91
Citation count690
Date of publishing2020 Nov 5
16 out of 17 COVID-19 patients with profound B-cell lymphopenia showed an effective improvement (in clinical symptoms and biological parameters) when treated with the passive transfer of COVID-19-neutralizing antibodies through CPT.
PMID 32959052
Title Convalescent plasma therapy for B-celldepleted patients with protracted COVID-19
Author(s) nameHueso T, Pouderoux C, Péré H, Beaumont AL, Raillon LA, Ader F, Chatenoud L, Eshagh D, Szwebel TA, Martinot M, Camou F, Crickx E, Michel M, Mahevas M, Boutboul D, Azoulay E, Joseph A, Hermine O, Rouzaud C, Faguer S, Petua P, Pommeret F, Clerc S, Planquette B, Merabet F, London J, Zeller V, Ghez D, Veyer D, Ouedrani A, Gallian P, Pacanowski J, Mékinian A, Garnier M, Pirenne F, Tiberghien P, Lacombe K.
Journal Blood
Impact factor10.66
Citation count9
Date of publishing2020 Nov 12
This case study is of an 80-year-old SARS-CoV-2 female patient who underwent acetylcysteine treatment to counteract Remdesivir associated acute liver failure.
PMID 33006138
Title Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) nameCarothers C, Birrer K, Vo M.
Journal Pharmacotherapy
Impact factor3.17
Citation count1
Date of publishing2020 Nov
This case study involves a 68-year-old SARS-CoV-2 positive female patient with a medical history of coronary artery disease, was treated with Remedesivir. The patient experienced associated acute liver failure, which improved with the treatment of acetylcysteine.
PMID 33006138
Title Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) nameCarothers C, Birrer K, Vo M.
Journal Pharmacotherapy
Impact factor3.17
Citation count1
Date of publishing2020 Nov
Compared to the control group patients (not-transfused), patients transfused within 72 hours of hospital admission had decreased mortality within 28 days. And a significant reduction in mortality was observed in patients transfused with high anti-RBD IgG titer COVID-19 convalescent plasma within 72 hours of admission.
PMID 32795424
Title Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality
Author(s) nameSalazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, Lopez BV, Eagar TN, Yi X, Zhao P, Rogers J, Shehabeldin A, Joseph D, Leveque C, Olsen RJ, Bernard DW, Gollihar J, Musser JM.
Journal Am J Pathol
Impact factor3.71
Citation count15
Date of publishing2020 Nov
A pregnant woman with severe COVID-19 was treated successfully with Tocilizumab and Remdesivir with better clinical improvement.
PMID 32618794
Title Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19)
Author(s) nameNaqvi M, Zakowski P, Glucksman L, Smithson S, Burwick RM.
Journal Obstet Gynecol
Impact factor3.78
Citation count5
Date of publishing2020 Nov
Compared to the HCQ alone or no treatment group patients, the combination-treated group patients (HCQ+ azithromycin) had a lower mortality rate.
PMID 32926573
Title Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19
Author(s) nameLauriola M, Pani A, Ippoliti G, Mortara A, Milighetti S, Mazen M, Perseghin G, Pastori D, Grosso P, Scaglione F.
Journal Clin Transl Sci
Impact factor3.75
Citation count5
Date of publishing2020 Nov
SARS-CoV-2 Patients associated with Severe Bronchospasm were treated with Ipratropium bromide, adrenaline, and magnesium sulfate.
PMID 33173630
Title Decreased Mortality in Patients With Severe Bronchospasm Associated With SARS-CoV-2: An Alternative to Invasive Mechanical Ventilation
Author(s) nameSalazar R Sr, Hallo A, Vasquez S, Reinthaller S, Echeverria J.
Journal Cureus
Impact factorCant find
Citation count1
Date of publishing2020 Oct 6
This case study is of a 53-year-old immunocompromised female patient who had recurring symptoms despite Remdesivir therapy and had to undergo convalescent plasma therapy for persistent improvement in health.
PMID 33103195
Title Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19
Author(s) nameMalsy J, Veletzky L, Heide J, Hennigs A, Gil-Ibanez I, Stein A, L√ľtgehetmann M, Rosien U, Jasper D, Peine S, Hiller J, Haag F, Schmiedel S, Huber S, Jordan S, Addo MM, Schulze Zur Wiesch J.
Journal Clin Infect Dis
Impact factor7.71
Citation count2
Date of publishing2020 Oct 26
Group of Patients treated with Arbidol recovered quickly from fever, stayed for a shorter duration in the hospital, and reported no side effects of the drug.
PMID 33097047
Title Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series
Author(s) nameGao W, Chen S, Wang K, Chen R, Guo Q, Lu J, Wu X, He Y, Yan Q, Wang S, Wang F, Jin L, Hua J, Li Q.
Journal Virol J
Impact factor2.45
Citation count1
Date of publishing2020 Oct 23
The group of patients treated with the HCQ showed no significant decrease in symptoms prevalence or severity over the 14-days study period compared to that of the placebo group.
PMID 32673060
Title Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 A Randomized Trial
Author(s) nameSkipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, Williams DA, Okafor EC, Pullen MF, Nicol MR, Nascene AA, Hullsiek KH, Cheng MP, Luke D, Lother SA, MacKenzie LJ, Drobot G, Kelly LE, Schwartz IS, Zarychanski R, McDonald EG, Lee TC, Rajasingham R, Boulware DR.
Journal Ann Intern Med
Impact factor11.75
Citation count83
Date of publishing2020 Oct 20
Lopinavir trough levels were found to be 2-fold higher in the COVID-19 patients and also appeared to be associated with C-reactive protein level.
PMID 32422065
Title Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)
Author(s) nameSchoergenhofer C, Jilma B, Stimpfl T, Karolyi M, Zoufaly A.
Journal Ann Intern Med
Impact factor11.75
Citation count14
Date of publishing2020 Oct 20
The prophylactic use of HCQ did not reduce the confirmed or probable COVID-19 disease in healthcare workers.
PMID 33068425
Title Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial
Author(s) nameRajasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pastick KA, Axelrod ML, Pullen MF, Nascene AA, Williams DA, Engen NW, Okafor EC, Rini BI, Mayer IA, McDonald EG, Lee TC, Li P, MacKenzie LJ, Balko JM, Dunlop SJ, Hullsiek KH, Boulware DR, Lofgren SM.
Journal Clin Infect Dis
Impact factor7.71
Citation count10
Date of publishing2020 Oct 17
Pharmacokinetic analysis of Remdesivir in two patients showed a peak in serum concentrations at the end of infusion, and decay after 1 h of infusion, while GS-441524 (plasma metabolite of the drug Remdesivir) reached a peak after 1 h of infusion and was detectable until the next dose of Remdesivir given.
PMID 32607555
Title Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19
Author(s) nameTempestilli M, Caputi P, Avataneo V, Notari S, Forini O, Scorzolini L, Marchioni L, Ascoli Bartoli T, Castilletti C, Lalle E, Capobianchi MR, Nicastri E, D'Avolio A, Ippolito G, Agrati C; COVID 19 INMI Study Group.
Journal J Antimicrob Chemother
Impact factor4.94
Citation count14
Date of publishing2020 Oct 1
After 14 days of Tocilizumab treatment, radiological improvement was observed in 68% of patients. The proportion of patients on invasive ventilation declined from 84% (on day 1) to 28% (on day 14).
PMID 32369191
Title Tocilizumab for the treatment of severe coronavirus disease 2019
Author(s) nameAlattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, Khatib MY, Aboukamar M, Abukhattab M, Alsoub HA, Almaslamani MA, Omrani AS.
Journal J Med Virol
Impact factor2.07
Citation count58
Date of publishing2020 Oct
3 Out of 4 patients treated with Remdesivir showed a clear clinical improvement and faster recovery. But one patient died due to multiple organ failures.
PMID 32418190
Title Early experience with remdesivir in SARS-CoV-2 pneumonia
Author(s) nameDurante-Mangoni E, Andini R, Bertolino L, Mele F, Florio LL, Murino P, Corcione A, Zampino R.
Journal Infection
Impact factor2.84
Citation count5
Date of publishing2020 Oct
Convalescent plasma therapy led to a resolution of ground-glass opacities and consolidation in five of six patients. CP therapy effectively eliminated the virus, with an immediate increase in anti-SARS-CoV-2 antibody titers in patients.
PMID 32293713
Title Treatment with convalescent plasma for COVID-19 patients in Wuhan, China
Author(s) nameYe M, Fu D, Ren Y, Wang F, Wang D, Zhang F, Xia X, Lv T.
Journal J Med Virol
Impact factor2.07
Citation count88
Date of publishing2020 Oct
This observational study is based on an algorithm that was structured to use tocilizumab for the treatment of COVID-19 patients with Cytokine Release Syndrome. Tocilizumab treatment showed positive survival outcomes in Mechanically ventilated patients.
PMID 32553536
Title Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes
Author(s) namePrice CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M.
Journal Chest
Impact factor7.22
Citation count41
Date of publishing2020 Oct
Patients treated with HCQ plus standard care showed no significant benefit in terms of the mortality rate and the need for ventilation. 6.2% of the patient died in the HCQ group, and 5.2% of patients died in the control group.
PMID 32828135
Title Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study
Author(s) nameAbd-Elsalam S, Esmail ES, Khalaf M, Abdo EF, Medhat MA, Abd El Ghafar MS, Ahmed OA, Soliman S, Serangawy GN, Alboraie M.
Journal Am J Trop Med Hyg
Impact factor2.25
Citation count12
Date of publishing2020 Oct